Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
13.56
+1.16 (9.35%)
At close: Dec 5, 2025, 4:00 PM EST
13.16
-0.40 (-2.95%)
After-hours: Dec 5, 2025, 6:34 PM EST
Aardvark Therapeutics Employees
Aardvark Therapeutics had 22 employees as of December 31, 2024.
Employees
22
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,216,909
Market Cap
295.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AARD News
- 10 days ago - Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - GlobeNewsWire
- 22 days ago - Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 24 days ago - Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 weeks ago - Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 - GlobeNewsWire
- 4 weeks ago - Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 weeks ago - Aardvark Therapeutics to Present at Upcoming Investor Conferences in November - GlobeNewsWire
- 6 weeks ago - Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek - GlobeNewsWire
- 2 months ago - Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - GlobeNewsWire